Phase I/II clinical trials of WT1 peptide-based immunotherapy have reported frequent clinical responses and significant tumor regression in leukemia, myelodysplastic syndrome, lung, and breast cancers [100,101,102,103]. This evidence concerns the gene WT1 and breast carcinoma.